# EDGAR Filing Document

**Accession Number:** 0001133416
**File Stem:** 0000000000-26-003426
**Filing Date:** 2026-4
**Character Count:** 2360
**Document Hash:** d18609950e0a18187bc501d48feb9512
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-003426.hdr.sgml**: 20260508

**ACCESSION NUMBER**: 0000000000-26-003426

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260406

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GALECTIN THERAPEUTICS INC
- **CENTRAL INDEX KEY:** 0001133416
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 043562325
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-294782

**BUSINESS ADDRESS:**
- **STREET 1:** 4960 PEACHTREE INDUSTRIAL BOULEVARD
- **STREET 2:** SUITE 240
- **CITY:** NORCROSS
- **STATE:** GA
- **ZIP:** 30071
- **BUSINESS PHONE:** 678-620-3186

**MAIL ADDRESS:**
- **STREET 1:** 4960 PEACHTREE INDUSTRIAL BOULEVARD
- **STREET 2:** SUITE 240
- **CITY:** NORCROSS
- **STATE:** GA
- **ZIP:** 30071

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRO PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20010612
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001140361-26-012329

## Text-Extract

```

                                                           April 6, 2026

Joel Lewis
Chief Executive Officer and President
Galectin Therapeutics Inc.
4960 Peachtree Industrial Blvd., Suite 240
Norcross, GA 30071

        Re: Galectin Therapeutics Inc.
            Registration Statement on Form S-3
            Filed March 31, 2026
            File No. 333-294782
Dear Joel Lewis:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Alan Campbell at 202-551-4224 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Brian Lee, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._